The Wisconsin Registry for Alzheimer's Prevention (WRAP) is a longitudinal observational cohort study enriched with persons with a parental history (PH) of probable Alzheimer's Disease (AD). Since late 2001, WRAP has enrolled 1,561 people at a mean baseline age of 54. Participants return for a second visit four years after baseline and subsequent visits occur every two years. Eighty-one percent (1270) of participants remain active in the study at a current mean age of 64 and 9 years of follow-up. Serially assessed cognition, self-reported medical and lifestyle histories (e.g. diet, physical and cognitive activity, sleep, and mood), laboratory tests, genetics, and linked studies comprising molecular imaging, structural imaging and cerebrospinal fluid data, have yielded many important findings. In this cohort, PH of AD is associated with 46% APOE ε4 positivity, more than twice the rate of 22% among persons without PH.
INTRODUCTION
While it is widely recognized that Alzheimer's Disease (AD) has an extended preclinical stage, the cognitive and neuropathobiological course of changes in late-middle-aged people who may later develop AD dementia are relatively unknown [1] . Such knowledge is crucial if AD is to be identified in its inchoate form, its pathogenesis illuminated, and the tempo and predictors of its progression characterized as a predicate to successful prevention trials.
The Wisconsin Registry for Alzheimer's Prevention (WRAP), established in 2001 [2] , is a longitudinal observational cohort of participants who enrolled at mid-life (mean age 54) , and that is enriched with risk for late onset AD due to parental history (PH) of AD.
The cohort also serves as a registry for linked studies. The overarching goals of the study shown in Table 1 are to identify early cognitive decline, and to characterize midlife factors associated with such decline and the contributing underlying biomarkers of AD and related pathology. The present contribution updates the initial description of the cohort, study design and protocol [2] , and provides new data on the effects of family history, APOE genotype and AD biomarkers on longitudinal cognitive decline over time.
Key study findings are summarized and future directions are presented.
-----------insert table 1 about here -----------------------
METHODS

Study Design
To the present, 1,561 participants have enrolled over a continuing enrollment window.
Recruitment sources included memory clinics in which a parent was diagnosed or treated, limited radio and newspaper advertisements and word of mouth. Participants generally met the following inclusion criteria at study entry: age 40 to 65; at least one biological parent diagnosed with dementia due to probable AD based on the NINDS-ADRDA criteria [3] , or neither biological parent with a diagnosis of AD; fluent English speaker; visual and auditory acuity adequate for neuropsychological testing; good health with no diseases expected to interfere with study participation over time.
Participants are excluded from enrollment if they have a prior diagnosis of dementia or evidence of dementia at baseline testing (1 was excluded due to baseline dementia).
The baseline mean age is 54, 73% have a parent with AD, and 40% of the total sample are APOE ε4 carriers (46% of the PH+ participants and 22% of the PH-participants).
Determination of parental history of AD: Three general methods were used to determine PH. First, direct diagnosis of the parent from study physicians or their affiliated faculty, or where medical records for the affected parent were available, a consensus panel of study investigators reviewed the parent's clinical evaluation for dementia to determine whether evidence was sufficient to diagnose probable AD.
Second, neuropathological confirmation of AD in the affected parent. Third, in the absence of sufficient prior information, a Dementia Questionnaire [DQ; 4] was conducted with the adult child regarding the parent's dementia history and course. The DQ asks about the type of dementia symptoms, the course of progression and the presence or absence of co-morbid conditions that could explain or contribute to the symptoms. Diagnostic classifications based on the DQ show very high sensitivity (100%) and specificity (90%) compared to clinical diagnosis [5] . Eight percent of PH subjects initially qualified for study entry by a parental autopsy; 83% by medical record review or expert physician diagnosis; and 9% by DQ. Less than 1% were self-report.
A comparison group without PH of AD:
To understand the role of parental history, recruitment of additional participants without PH began in 2004. This group now consists of 421 persons who by self-report did not have a parent with dementia due to AD or related cause, and who in general have a mother who survived to at least age 75 and a father to at least age 70 without dementia. Because parental status changes over time, it is reassessed at each visit and updated as necessary (e.g. in the case that a previously non-demented parent later developed dementia or, rarely, a parent whose dementia was presumed due to AD was later found by autopsy to be another pathology).
Study Visit Procedures:
Participants are followed at regular intervals with detailed in-person assessments, questionnaires, and blood collection occurring at each study visit. The first follow up is approximately 4 years after baseline, and further follow up visits are approximately every two years. Persons will remain in the study until age 85, unless they withdraw, convert to dementia, or develop another illness precluding participation or accurate assessment of cognition. Each visit requires approximately six hours and comprises the assessments shown in Table 2 i.e. cognitive measurement, anthropometric measures, laboratory tests, and questionnaire ratings completed by the participant and an informant including the Quick Dementia Rating System or Clinical Dementia Rating [6] .
Reliability and consistency of cognitive testing is established through regular review of aspects of testing procedures at team meetings, biannual individual observations of test administration, through adherence to a standardized manual of procedures, and through blinded rescoring by a separate rater (20% annually for each psychometrist).
Consent for Brain donation:
Neuropathologic confirmation is critical for linking cognitive trajectories to disease-related endpoints. Accordingly, participants are encouraged to enroll in the Wisconsin Brain Donation Program which is administered by the Neuropathology Core of the Wisconsin Alzheimer's Disease Research Center.
Brain bank enrollment has not been an entry criterion. However, since 2015 brain donation has been systematically discussed with participants at each visit, and educational material on the value of brain donation is regularly offered at WRAP's statewide information sessions and in semi-annual newsletters.
Identifying subtle, preclinical impairment:
A critical issue for the field is development and validation of optimal methodology for identifying early cognitive decline/impairment [7] . Simple single-test thresholds are insufficient [8] and available published norms used to define 'impaired' and 'normal' performances on neuropsychological tests in persons age ~55+ may be confounded by unintended inclusion of individuals with incipient disease in the normative samples of those tests [9] [10] [11] , thereby reducing sensitivity to subtle dysfunction [10] . Moreover, thresholds and norms may have been validated by others in populations of uncertain relevance to the cohort under investigation. To avoid these potential confounders, and to enhance sensitivity to preclinical decline, we developed a 'robust' norms approach in which internal normative distributions for cognitive factor scores [12] and individual test scores [13] , are generated, where 'robust'
indicates that the normative group is non-declining over time. In Koscik et al. [12] , deficits on multiple visits via algorithmic criteria were required as evidence of "psychometric MCI" while in Clark et al. [13] , deficits on multiple tests within a specific domain were required to identify persons with psychometric MCI. In practice, and to ensure that these approaches are not over-identifying people with abnormal cognition, we incorporate these algorithms into our consensus review process as described in the next section.
Classification of cognitive status:
If cognitive abnormalities are detected by algorithm on neuropsychological tests, data from participant visits are brought to a consensus review committee consisting of dementia specialist physicians, neuropsychologists and nurse practitioners for in-depth review. Thresholds for committee review include performance greater than 1.5 SD below robust internal norms adjusting for age, gender, and literacy-level [12, 13] , self or informant report of cognitive or functional decline on [7] and requires a) patient or informant concern regarding change in cognition, b) unambiguous impairment in one or more cognitive domains, c) not meeting criteria for dementia. The experimental category of "early MCI" is assigned if there is lower than expected objective performance (typically >1.5 SD below internal robust norms), but few or no subjective cognitive complaints or clinically significant deficits [for further discussion see 14] .
Biomarker and genetics procedures:
A diversity of MRI, molecular PET and CSF biomarkers have been acquired from subsets of participants as funding permits (see Supplemental Table for sample sizes of each to date). Serial MRI's and LP's will be obtained from approximately 60% of WRAP participants over the next 5 years and serial amyloid and tau imaging will be obtained from approximately 30% with current and projected funding. Genetics: APOE ε2/ε3/ε4, 20 common genetic variants from the International Genomics of Alzheimer's Project consortium [24] , and low frequency variants in TREM2 [25, 26] and PLD3 [27] were genotyped using competitive allele-specific PCR based KASP genotyping assays (LGC Genomics, Beverly, MA). Duplicate quality control (QC) samples had 99.9% concordance. Cross-validation of APOE genotypes with prior assays was 99.7% concordant. Various polygenic risk scores are derived in which the contribution of each SNP to the score is weighted by its risk odds ratio [28] .
More recently genome-wide genotyping was performed using the Illumina Infinium Expanded Multi-Ethnic Genotyping Array (MEGA EX ) containing approximately 1.7 million genetic markers. Accrual is shown by visit number together with mean age at each visit. The rolling recruitment window means that individual participants have a different number of follow up visits to date depending on how long they have been in the study. Sixth visits began in late 2016. Over 5600 study visits have occurred since inception, and over 3000 visits are projected over the next five years. Retention is 82% over the 16-year study period.
REVIEW OF SELECT STUDY FINDINGS AND NEW RESULTS
Accrual
Descriptive information: Baseline characteristics of the WRAP sample, including demographics, medical history, and cognition, are described in Table 3 . In keeping with the original study design, Table 3 is stratified by parental family history and APOE ε4 carrier status. Histograms showing the sample ages at baseline and at last visit are provided in Figure 2 .
-----------insert Table 3 
Previously published findings:
As noted in the Methods section, we developed and evaluated two cross-sectional algorithms for identifying performance that is below robust internal norms using factor scores [12, 29] and using individual test scores [13] . Compared to the use of published norms in the same cohort, both psychometric approaches demonstrate improved sensitivity to small but consequential decrements of cognitive function. With the factor score approach [12] , we observed greater longitudinal cognitive decline among the 13% of the cohort who were classified as psychometric MCI compared do those who were cognitively normal. Using this approach, we also showed that psychometric MCI is associated with greater dysfunction in connected language [30] and verbal fluency [31] .
Using the cognitive test approach [13] , the false positive rate was reduced by requiring a pattern of lower than expected performance on multiple tests within or across domains to be affected in order for the participant to be designated as having MCI [similar to 32, 33] . With use of this "multi-test, single visit" approach, 18% of participants were classified as having psychometric MCI. These algorithmic approaches may serve in their own right as intermediate outcomes, and are used to inform research visit-by-visit diagnoses made by the diagnostic consensus committee. In analyses of consensus committee classified cognitive status, higher intra-individual cognitive variability at baseline (IICV) predicted impaired cognitive status 8-10 years later [14] .
New results: Currently 15.2% of the cohort met early MCI criteria at their last study visit while 2.3% met criteria for MCI and 0.1% met criteria for dementia due to AD.
Prevalence for early MCI at the most recent visit was associated with age, ranging from approximately 6 percent for the youngest participants to 20 percent for those over 70.
Prevalence of early MCI, MCI, and dementia by last visit age are shown in Previously published findings: In addition to identifying specific individuals with cognitive impairment, the study seeks to understand how parental history of AD and APOE ε4 status (both major risk factors) affect cognitive trajectories from midlife. Earlier crosssectional analyses of WRAP cognitive data suggested modest relationships between cognitive performance and genetic and/or familial risk factors. For example, at the first visit, PH+ and PH-participants had similarly high scores on a list-learning task, but PH+ participants relied more heavily on recent list items, suggesting greater difficulty with consolidation [34] .
As expected, WRAP PH+ participants are more than twice as likely to be APOE ε4 positive (see Table 2 ). They are also more likely to carry the TREM2 T risk allele [35] . As well, genetic risk features for AD may interact with one another. Two variant alleles of the ABCA7 gene are associated with worse memory and executive function scores in participants with no APOE-ε4 alleles, but with better scores in those with 1 or 2 APOEε4 alleles [36] . To the present, longitudinal comparisons have not detected effects of these genetic markers on cognitive trajectories [35, 36] . Boots et al. [37] examined the influence of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on cognitive trajectories and PET amyloid load. Compared with Val carriers, BDNF Met carriers exhibit greater decline over time on the Verbal Learning and Memory factor score. In the subset with amyloid imaging, amyloid burden modified the relationship such that those with high amyloid burden who were also BDNF Met carriers exhibited steepest cognitive decline. The aggregate effects of 21 genetic risk alleles on cognition via a polygenic risk score (PRS) identified modest negative effects on working memory performance, but not other domains [28] . Darst and colleagues [28] also examined PRSs specific to causal pathways implicated in AD. Gene clusters affecting Aβ clearance and cholesterol metabolism were strongly predictive of CSF Aβ 42 , CSF Aβ 42 /Aβ 40 , and PiB amyloid burden, as was APOE when considered as an independent predictor on its own [see also 22] .
New results: To explore the effects of PH on longitudinal cognitive trajectories, we modeled the trajectories with a linear mixed effects model [38, 39] using random intercepts at the family and participant levels, and a random age slope at the participant level. Fifty-nine participants reporting neurological diagnoses at baseline were excluded from these analyses. Baseline characteristics of this subset were virtually identical to those in Table 3 . Covariates included age (linear and quadratic age terms were tested), sex, race, education level, and baseline literacy (WRAT-III Reading), and the number of prior exposures to the neuropsychological test battery [40] . The effects of interest are:
(1) the main effects of APOE and PH (baseline effects); (2) their interaction with age (longitudinal effects); and (3) their interaction with prior test exposure, that accounts for the differential benefit from practice. Table 4 lists estimates for each of these terms for Verbal Learning and Memory, an important composite outcome for early cognitive change [29] . Predicted trajectories with age are plotted by APOE and PH status in ---insert figure 4 about here ---Although small decrements in performance occur with increasing age, little evidence is observed in these data for effects of APOE or PH on cognitive performance, either in the main analysis or in secondary analyses that (a) excluded participants whose parents developed AD after age 75 and (b) modeled cognition as a function of APOE genetic risk score rather than an APOE ε4 binary status variable [28] . The lack of APOE or PH risk effects on cognition is unlikely to be due to lack of power. Prospective power calculations using Monte Carlo simulations (k=1000) indicated power of 0.95 or greater to detect small main effects (mean performance approx. 0.2 SD lower for the highestrisk group), and age interactions (age-related slope approx. 20% steeper for the highest-risk group). Because the cohort is still relatively young (current mean age 64) and will continue to be followed to determine if an effect unfolds with older age, we caution that the current reported absence of an effect in these data should not be accepted as definitive for the WRAP cohort.
For the subsample who underwent amyloid imaging or CSF and on whom Aβ42 assay results were available (N=211), we classified each participant as amyloid-positive (n=62; 29%) or amyloid-negative (n=149; 71%) using cutoffs described elsewhere [16] (Clark et al. in review) . In this subset, amyloid positivity was significantly related to PH ( Table 5; χ 2 = 14.22, p = 0.003). However, follow-up tests indicated the association was largely explained by APOE ε4 carrier status (χ 2 = 12.82, p < 0.001) rather than an independent effect of PH specifically (χ 2 = 0.88, p = 0.35). The significant relationship between APOE ε4 status and amyloid status holds even after controlling for age at the date of biomarker assessment (logistic regression: β APOE = 1.263, p < 0.001). In a smaller subsample for whom longitudinal amyloid (PiB) data were available (N=142), conversion from amyloid-negative to amyloid-positive was associated with carriage of at least one APOE ε4 allele (χ 2 = 4.24, p = 0.04) but not with PH, baseline age, gender, or consensus conference diagnosis (all p > 0.10). Together with the null cognitive findings, these results are consistent with a prevailing biomarker model in which AD pathophysiology precedes cognitive change [1, 41] . The WRAP study spans a period of scientific development in which risk factors like APOE status and PH have given way to more direct biomarkers of AD pathophysiology for characterizing the preclinical stages of AD [1, [41] [42] [43] [44] , and less specific brain markers of function and health such as functional and structural MRI have become gauges of the effect of AD pathophysiology on brain function and neurodegeneration. Early structural and functional MRI studies in WRAP (uninformed by AD pathophysiology biomarkers of amyloid and tau) found differences in cerebral activity during memory tasks [45] [46] [47] diffusion tensor imaging [48] and hippocampal morphology [49] as a function of PH or APOE ε4 status. These were interpreted as potentially related to differential AD pathophysiological processes in the PH group, though there was nothing specific to ADpathology about the imaging at the time or about the risk features that participants were stratified by.
Results and Discussion related to
More recently, the effects of CSF Aβ42 and tau, and amyloid PET imaging using [C- 11] PiB have been examined as indices of the presence or absence of AD. In n=201 WRAP participants with PiB PET data at a mean age of 61 there was no significant relationship with concurrent cognition [23] . This finding was not surprising as amyloid load is expected to increase prior to cognitive loss. Subsequently Clark et al. [50] tested cognitive changes over time with mixed effects models, and found that greater overall amyloid burden via PiB PET was associated with a greater decline on composite test performance in episodic memory and executive function [50] . Similar results have been found with CSF derived estimates of amyloid and tau burden (Clark et al. in review) suggesting that subthreshold effects of AD pathophysiology may be present that reflect the gradual continuous process of AD pathology accumulation. Moreover, other data suggest that AD pathology in the late-midlife preclinical time frame may co-exist with atrophy and/or vascular and other diseases that have secondary effects on neural tissue. Racine et al. [16] used hierarchical clustering analysis of amyloid burden, tau burden, white matter hyper-intensities and hippocampal atrophy to categorize WRAP and comparable Wisconsin ADRC participants with imaging and CSF data. Four clusters emerged including: 1) participants with preclinical AD who were predominantly positive for tau and amyloid; 2) participants with mixed vascular and AD pathology who exhibited white matter hyper-intensities as well as variable AD pathology; 3) participants with suspected non-AD pathology who exhibited atrophy but not Aβ or tau pathology; and 4) participants with healthy aging who exhibited normal imaging and CSF biomarkers. The greatest decline on memory tests over time was observed in the preclinical AD cluster. Taken together, these findings indicate that biomarkers of AD pathophysiology are sensitive to cognitive decline in late middle-aged WRAP participants. As the cohort ages and individuals develop age-related diseases, biomarker profiles will likely become more heterogeneous. Thus, models examining change in biomarkers and cognition over time must include more precise markers of other pathologies as they become available.
Results and Discussion related to Goal 4:
Characterize the influence of health behaviors on risk and resilience to brain pathology and cognitive decline due to underlying AD.
Previous findings:
The effects of modifiable risk factors on cross-sectional cognition have been the target of multiple WRAP investigations. Cognitive activity throughout the lifespan measured by education level [21] , job complexity [51] , and selfreported current participation in stimulating activities such as games [52, 53] , are associated with better performance in several cognitive domains. Participants with greater numbers of stressful life events perform worse on measures of cognitive speed and flexibility, and conversely, in participants with greater social support performance is better [54] . Of note, the protective effect of social support is diminished by presence of APOE ε4 [55] . Sleep adequacy in WRAP participants is associated with amyloid burden assessed with amyloid imaging [56] and CSF Aβ42 and tau levels [18] . Cardiovascular and metabolic fitness also appear to have a protective effect on gray matter, cerebral blood flow and episodic memory performance. Insulin resistance in particular is linked with cerebral atrophy, amyloid burden, CSF biomarkers of AD, and lower cerebral glucose uptake [57] [58] [59] [60] [61] [62] .
Physical Activity (PA) and brain health: PA and related variables including cardiorespiratory fitness (CRF) are well-studied protective factors for AD, with a recent evidence review identifying PA as the modifiable factor with the highest impact on reducing the national prevalence of AD [63,but see also 64]. Cross-sectional WRAP publications elucidate the relationship between PA, cognition, brain structure, and neuropathological markers of AD among normal adults. In n=315 WRAP participants, Boots et al. [65] found that engagement in PA was associated with preserved volume in diverse brain regions including the medial and lateral temporal lobe and medial parietal lobe, together with reduced white matter ischemic lesions and with fewer memory complaints. Dougherty et al. [66] assessed PA via accelerometer in 91 WRAP participants, and found that those meeting recommended PA levels had greater temporal lobe regional volumes including the hippocampus compared to those who did not meet recommended activity levels. In addition to effects on brain structure and cognition, PA moderated the effect of age [67] and genetic risk factors [68] on AD pathophysiological biomarkers in WRAP participants. Specifically, Okonkwo et al. [67] report that a history of PA was associated with an attenuation of age-related alterations in β-amyloid (Aβ) burden, cerebral glucose metabolism, and hippocampal volume.
Similarly, Schultz et al. [22] found that CRF attenuated the adverse influence of cholesterol metabolism polygenetic risk on CSF biomarkers. Of note, the beneficial effect of PA on the brain substrates of cognitive health may depend on level of exercise intensity [69] .
In aggregate these associational studies in WRAP participants suggest that modifiable factors such as physical and cognitive activity, glucose and metabolic regulation, stress and sleep may be avenues for interventions that enhance brain health and reduce the likelihood and severity of AD pathology. (and now annual) information sessions with participants to share back what we are learning serve to educate participants on the overarching importance of biomarker enrollment and brain donation, and are also an effective retention component. Although PH as an enrichment factor has been supplanted in part by the capability to directly measure AD pathology in vivo, the experience of having a parent with AD motivates many of our participants to remain in WRAP and take part in linked studies at a high level of volunteerism. A caveat is that the participant characteristics are biased toward and most generalizable to persons who have a parent with AD by design. The cohort is also biased in other ways. Because WRAP is a self-selected sample of convenience, the majority of the cohort are Caucasian (88%), women (71%), and highly educated [70] , a meta-analysis of APOE and sex on dementia incidence [71] , and a study involving predictive algorithms for MCI in a consortium of five preclinical AD or adult children cohorts [72] .
The WRAP observational longitudinal cohort is AD risk-enriched, and has been followed with detailed measurements since midlife. This is a time frame that is less well studied than older ages, but is nevertheless a critical epoch, as this is when AD pathology likely begins and when its trajectory may be modifiable through pharmacologic and/or lifestyle approaches.
Table 1. The Major Goals of the WRAP study
1: Determine whether AD-related cognitive trajectories can be detected in midlife and distinguished from normal aging using sensitive cognitive assessments. 2: Determine the effect of genetic vulnerability on AD-related cognitive trajectories and biomarkers. 3: Determine the biomarker patterns associated with cognitive trajectories and the development of symptomatic cognitive dysfunction. 4: Examine the influence of health behaviors on risk and resilience to brain pathology and cognitive decline due to AD. Notes: Except where otherwise indicated, reported values are percentages, and comparisons were performed using a Fisher's exact test. † Mean (SD); p-values obtained via ANOVA. § Median (range); p-values obtained via a nonparametric (Kruskal-Wallis) test. 0.0389 0.0584 PH-/ε4-----Notes: Coefficients for a linear mixed model of Verbal Learning and Memory performance created using SAS PROC MIXED. Random intercepts were modeled for families and subjects nested within families; age was also included as a subject-level random effect (allowing change with age to vary by individual). F-statistics for fixed effects were calculated using the Kenward-Roger approximation for denominator degrees of freedom. 
